# A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects

> **NCT01611467** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 18 (actual)

## Conditions studied

- Safety and Pharmacokinetics in Healthy Volunteer Subjects

## Interventions

- **DRUG:** CC-223
- **DRUG:** CC-223

## Key facts

- **NCT ID:** NCT01611467
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-01
- **Primary completion:** 2012-07-01
- **Final completion:** 2012-07-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01611467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01611467, "A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01611467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*